Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Exanthema × capivasertib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Leukemia 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Meningioma 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Exanthema 1 Endometrial Neoplasms 1 Disease Progression 1 Diarrhea 1 Chondrosarcoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1 Advanced Gastric Cancer 1 Advanced Cancer 1 Advanced Breast Cancer 1 Adenocarcinoma 1

Interventions

Fulvestrant 2 ruxolitinib 1 dexpanthenol 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Provitamins 1 Prednisone 1 Loperamide 1 Interviews as Topic 1 HIV Testing 1 Gels 1 Fibroblast Growth Factor 7 1 Doxycycline 1 Dapsone 1 Cetuximab 1 Anti-Bacterial Agents 1 Alpelisib 1 Acitretin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07426822 2026-02-24

SAFE-CAP

Yale University

Phase 2 Not yet recruiting

Diarrhea, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡